













# NMPA



-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_
-  \_\_\_\_\_




??? ????????





24



24



5



3

??? ?????







??? ??













[Redacted]  
[Redacted]

[Redacted]  
[Redacted]

3. ??????????

[Redacted]  
[Redacted]

4. ?????????????????

[Redacted]

???????????

[Redacted]  
[Redacted]

1. ?????????????

[Redacted]  
[Redacted]  
[Redacted]

2. ?????????????

[Redacted]

[Redacted]

FDA PMDA [Redacted]  
[Redacted]

EMA

“  
2019 25 ” [Redacted]

[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]











????????????????????

???????

locally applied, locally acting products LALAP

locally applied, locally acting products LALAP

locally applied, locally acting products LALAP

locally applied, locally acting products LALAP ICH

locally applied, locally acting products LALAP

???????

locally applied, locally acting products LALAP

????????????????????

locally applied, locally acting products LALAP

locally applied, locally acting products LALAP

locally applied, locally acting products LALAP











use in the treatment of asthma in children and adolescents,2009.

7. FDA□ Guidance on Topical Dermatologic Corticosteroids: in vivo bioequivalence, 1995.

















[Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]

[Redacted]

3

[Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]

[Redacted]  
 [Redacted]  
 [Redacted] " [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]

????????

[Redacted]  
 [Redacted]  
 [Redacted]

[Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 [Redacted]

[Redacted]  
 [Redacted]  
 [Redacted]

"

-

????

[1] ICH. E1: The extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-term Treatment of Non- life-threatening Conditions [EB/OL]. Oct 1994.

<https://www.cde.org.cn/ichWeb/guidelch/toGuidelch/3/0>

[2] [ICH. E5\(R1\): Ethnic Factors in the Acceptability of Foreign Clinical Data](#) [EB/OL]. Feb 1998.

[3] [ICH. E8\(R1\): General Considerations for Clinical Trials](#) [EB/OL]. Oct 2021.

[4] ICH. E9: Statistical Principles for Clinical Trials [EB/OL]. Feb 1998.

<https://www.cde.org.cn/ichWeb/guidelch/toGuidelch/3/0>

[5] ICH. E10: Choice of Control Group and Related Issues in Clinical Trials [EB/OL]. July 2000. <https://www.cde.org.cn/ichWeb/guidelch/toGuidelch/3/0>

[6] ICH. E17: General principle on planning and Designing Multi-Regional Clinical Trials [EB/OL]. Nov 2017. <https://www.cde.org.cn/ichWeb/guidelch/toGuidelch/3/0>

[7] ICH. E19 A Selective Approach To Safety Data Collection In Specific Late-Stage Pre-approval Or Post-Approval Clinical Trials [EB/OL]. Sep 2022.

<https://www.cde.org.cn/ichWeb/guidelch/toGuidelch/3/0>

[8] [国家药品监督管理局](#) . [国家药品监督管理局](#) [EB/OL] 2017 1 .

<https://www.cde.org.cn/zdyz/domesticinfopage?zdyzldCODE=b32eaabf2c4cc56570c23c19f9608076>

[9] [国家药品监督管理局](#) . [国家药品监督管理局](#) [EB/OL] 2022 5 .

[10] [国家药品监督管理局](#) . [国家药品监督管理局](#)

2020 82 [EB/OL] 2020 7 .

<https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200708151701834.html>




[11] [国家药品监督管理局](#) . [国家药品监督管理局](#) [EB/OL] 2020 12 .

<https://www.cde.org.cn/zdyz/domesticinfopage?zdyzldCODE=35d77016fdcd7dc0be456d8cf17ae238>


??

????????????????????????????????

?????



????????????????



??????????



??????????

1. [ ]











1 " " A-H  
" " 0 7 " "

TDS  
TDS 24  
72 4 8

MIS  
" " " "  
TDS  
MIS

6.

PPS 21 24  
TDS TDS 21  
3 TDS  
TDS LOCF PPS

TDS I/S RLD RLD TDS MIS  
6 0.20 " "  
" " 230 RLD TDS MIS

TDS

236 TDS %  
48 72  $\geq 2$

PPS 21 48 24 TDS  
TDS 48 72 1 48 TDS  
24 48 72 LOCF



[2] FDA. Assessing the Irritation and Sensitization Potential of Generic Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry [EB/OL]. Apr 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas>.

[3] EMA. Guideline on the pharmacokinetic and clinical evaluation of modified release 279 dosage forms [EB/OL]. Nov 2014. <https://www.ema.europa.eu/en/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms-scientific-guideline>

[4] [REDACTED] . [REDACTED] [EB/OL]. 2022 [REDACTED] 5 [REDACTED] .

[5] [REDACTED] . [REDACTED] IVRT [REDACTED] IVPT [REDACTED] [EB/OL]. 2025 [REDACTED] 6 [REDACTED] .

[6] FDA. Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications [EB/OL]. Jul 2021. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-adhesion-topical-and-transdermal-systems-submitted-new-drug-applications>.











??

?

????

single arm trial SAT

randomized controlled

SAT RCT SAT

randomized controlled

SAT RCT SAT

SAT RCT

RCT RCT

RCT

SAT

SAT

" "

SAT SAT

SAT

"

"

cell and gene therapy, CGT

good clinical practice GCP

good clinical practice GCP

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH

??

SAT

SAT

SAT

SAT

SAT

RCT









